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Background
The role of δ opioid receptors in opioid antinociception
and tolerance development is still unclear. In the spinal
cord of morphine-tolerant mice δ receptor ligands given
intrathecally (i.t.) differently influenced the antinocicep-
tive effect of the μ agonist D-Ala2-methyl-glycinol
(DAMGO). The δ1 agonist D-Pen2,5-enkephalin (DPDPE)
inhibited, the δ2 agonist deltorphin II did not alter, and
the δ antagonist cha-TIPPψ potentiated the effect of
DAMGO. We hypothesized that during the development
of morphine tolerance the formation of μ-δ heterodimers
may contribute to the spinal μ opioid tolerance. Delta lig-
ands may affect the dimer formation differently. Those,
like DPDPE may facilitate the dimer formation, hence
inhibit the antinociceptive effect of DAMGO by causing
virtual μ receptor down-regulation. Ligands that do not
affect the dimer formation do not influence antinocicep-
tion but ligands with the presumed capability of discon-
necting the dimers may decrease the spinal tolerance to
DAMGO. The δ ligand profile in morphine-tolerant rats,
were also studied.
Methods
Male Wistar rats (150-200 g) were treated with subcutane-
ous (s.c) morphine twice daily for four days with increas-
ing doses (50, 100, 200, 200 μmol/kg). On the fifth day
the antinociceptive effect (rat tail flick test) of DAMGO
was measured alone and combined with a fixed dose of δ
ligands given i.t.: DPDPE, Ile3,5-deltorphin II, cha-TIPPψ
and naltrindole, respectively.
Results
The repeated treatment with morphine resulted in
approximately three to six-fold shift of the ED50 value of
DAMGO compared to that of naive rats. Both in naive
control and morphine-tolerant rats all ligands except nal-
trindole potentiated the antinociceptive effect of i.t.
DAMGO (two to five-fold). In the tolerant rats the poten-
tiation restored the potency of DAMGO to the control
level.
Conclusion
Delta ligands behave differently in rats than in mice. One
possible explanation could be a higher basal density of
the μ-δ heterodimers in rats. The inhibitory action of nal-
trindole on the antinociceptive effect of DAMGO could be
explained by its relatively low μ/δ selectivity as well as by
the different effect on the μ-δ heterodimer. The difference
in the DPDPE effect in morphine-tolerant rats and mice
requires further clarification.
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